Adjuvant Trastuzumab Emtansine Improves Overall Survival in HER2+ Breast Cancer

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 16, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, Jan. 16, 2025 -- For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall survival more than trastuzumab alone, according to a study published in the Jan. 16 issue of the New England Journal of Medicine.

Charles E. Geyer Jr., M.D., from the National Surgical Adjuvant Breast and Bowel Project Foundation in Pittsburgh, and colleagues randomly assigned patients with HER2-positive early breast cancer with residual invasive disease in the breast or axilla after neoadjuvant systemic treatment with taxane-based chemotherapy and trastuzumab to receive 14 cycles of T-DM1 or trastuzumab (743 individuals in each treatment group).

With a median follow-up of 8.4 years, the researchers found that T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab (unstratified hazard ratio for invasive disease or death, 0.54; 95 percent confidence interval, 0.44 to 0.66). Seven-year invasive disease-free survival was 80.8 and 67.1 percent with T-DM1 and trastuzumab, respectively. A significantly lower risk for death was seen with T-DM1 versus trastuzumab (unstratified hazard ratio, 0.66; 95 percent confidence interval, 0.51 to 0.87; P = 0.003). Seven-year overall survival was 89.1 and 84.4 percent, respectively, with T-DM1 and trastuzumab. In 26.1 and 15.7 percent of patients in the T-DM1 and trastuzumab groups, respectively, adverse events of grade 3 or higher were noted.

"This prespecified long-term follow-up analysis provides additional support for the neoadjuvant therapy paradigm by showing that adjuvant T-DM1 also provided a significant improvement in overall survival and no evidence of long-term safety issues," the authors write.

The study was funded by F. Hoffmann-La Roche/Genentech, the manufacturer of trastuzumab emtansine.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-01-17 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords